Voyager reports 1b Parkinson's progress, page-3

First 3 Last

Share
Profile

Follow
skint

3,630 Posts.

116

11/11/18

13:22

Post #: 36462121
Share

Originally posted by pivalde: ↑

Skint, very interesting drug. To understand it a bit more I post here how it works. As you can see it does not prevent death of brain cells as I do hope PBT434 does in humans and has been demonstrated to be true in animal studies. Best to read it your self:
"The progressive motor symptoms of Parkinson’s disease are largely due to the death of dopamine neurons in the substantia nigra, a part of the midbrain that converts levodopa to dopamine, in a single step catalyzed by the enzyme AADC. Neurons in the substantia nigra release dopamine into the putamen where the receptors for dopamine reside. In Parkinson’s disease, neurons in the substantia nigra degenerate and the enzyme AADC is markedly reduced in the putamen, which limits the brain’s ability to convert oral levodopa to dopamine⁴. The intrinsic neurons in the putamen, however, do not degenerate in Parkinson’s disease⁵^,⁶. VY-AADC, comprised of the adeno-associated virus-2 capsid and a cytomegalovirus promoter to drive AADC transgene expression, is designed to deliver the AADC gene directly into neurons of the putamen where dopamine receptors are located, bypassing the substantia nigra neurons and enabling the neurons of the putamen to express the AADC enzyme to convert levodopa into dopamine. The approach with VY-AADC, therefore, has the potential to durably enhance the conversion of levodopa to dopamine and provide clinically meaningful improvements by restoring motor function in patients and improving symptoms following a single administration".

Expand

Yes I agree, VY-AADC is a totally different class of drug, and the action of PBT434 of the rescue of failing SN neurons would seem to be superior. I do like the way Voyager was able to deliver some efficacy results from the phase 1 trials.
With cash close to 200m and market cap of 400m Voyager have an enterprise value of around 200m. I think it is amazing no Pharmas are interested in Prana at this very low price.

Last edited by skint: 11/11/18

PBT Price at posting: 4.3¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

HotCopper Highlights: Your most watched stocks for Week 47, 2024

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

There are more pages in this discussion • 5 more messages in this thread...

First 3 Last

Add PBT (ASX) to my watchlist

Voyager reports 1b Parkinson's progress, page-3

Top Stories

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Scientific conference spotlights PYC's work on blindness disease treatment

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Sales growth pushes Lovisa's fortunes (and shares) upwards

Featured News